Lecanemab for early Alzheimer's disease with amyloid buildup
Treatments studied
Part of Brain & nervous system, Mental health clinical trials.
This trial tests lecanemab, an infusion medicine that targets amyloid protein buildup in the brain, in people with mild cognitive impairment or mild Alzheimer's disease. Researchers will track how well it works and study how it affects your body's proteins using advanced lab tests.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 50–90 years old
- Diagnosed with mild cognitive impairment (MCI) or mild Alzheimer's disease with confirmed amyloid protein buildup in the brain (shown by PET scan or spinal fluid test)
- Memory and thinking scores in a specific range (MMSE ≥20; CDR score 0.5 or 1)
- A reliable caregiver who can attend visits and help you take the study medication
- No major stroke, mini-stroke, or seizure in the past year
- No moderate-to-severe depression, suicidal thoughts, or psychiatric symptoms that would interfere with the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether the drug lecanemab works better at different doses for people with early Alzheimer's disease or mild cognitive impairment caused by Alzheimer's. It aims to see if the drug can slow memory loss in real-world situations.
This study tests whether a special 3Tesla MRI scan can improve how well antibody treatments work for people with early Alzheimer's disease. The goal is to see if the scan helps make the treatment more effective and safer.
This study tests a drug called Lecanemab in people with early Alzheimer's. It uses a blood test to see how well the drug works. You may qualify if you have mild Alzheimer's or mild cognitive impairment due to Alzheimer's and have a positive amyloid test.
This study looks at how well lecanemab works for people with early Alzheimer's disease. It aims to see if the drug can help slow down memory and thinking problems.
This study tests how lecanemab works in people with early Alzheimer’s, including those with mild dementia or mild memory problems. It aims to see if the drug can help clear brain plaques and slow down symptoms.
This trial tests an investigational drug called lencanumab for people with early Alzheimer's disease. The goal is to see if it can help with memory and thinking by targeting brain changes caused by Alzheimer's.
Hear when a new Alzheimer s Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.